6:28 PM
 | 
Jan 15, 2013
 |  BC Extra  |  Company News

EC approves Lilly's imaging agent Amyvid

The European Commission approved Amyvid florbetapir from Eli Lilly and Co. (NYSE:LLY) as a PET imaging agent to estimate beta amyloid neuritic plaque density in patients with cognitive impairment who are...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >